If you've ever found yourself feeling increasingly drawn to a stock that's constantly rising in price, you are not alone... Since the dawn of the stock market, speculators have been captured by the tendency of prices to 'trend'. When...
ADAP — Adaptimmune Therapeutics Share Price
0.000.00%
Last Trade - 00:00HealthcareSpeculativeMid CapFalling Star
- $601.78m
- $283.83m
- $3.63m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 14.2 | 37.83 | 59.51 | 1.12 | 3.96 | 3.21 | 16.05 | -15.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for ADAP
Anyone familiar with stock market screeners will know that shares in Adaptimmune Therapeutics (NSQ:ADAP) have been in an uptrend in recent months, with strong relative price strength on a 1-month, 6-month and 12-month basis.Knowing exa...
Studies by leading experts into the power of price momentum show that stocks with the strongest price trends tend to keep up the pace for anywhere up to one year. A big part of the reason for this is down to investor psychology. With...
Profile Summary
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.
Directors
- David Mott NEC
- Adrian Rawcliffe CEO (48)
- Gavin Wood (50)
- William Bertrand (55)
- Elliot Norry (57)
- John Lunger (51)
- Helen Tayton-Martin OTH (53)
- James Noble NED (62)
- Lawrence Alleva (71)
- Ali Behbahani (43)
- Barbara Duncan (56)
- John Furey (55)
- Elliott Sigal (69)
- Tal Zvi Zaks (55)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- December 3rd, 2014
- Public Since
- May 6th, 2015
- No. of Shareholders
- 27
- No. of Employees
- 462
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 932,984,520
- Address
- 60 Jubilee Avenue, ABINGDON, OX14 4RX
- Web
- https://www.adaptimmune.com/
- Phone
- +44 1235430000
- Auditors
- KPMG LLP
Latest News for ADAP
Upcoming events for ADAP
Q3 2021 Adaptimmune Therapeutics PLC Earnings Release
Similar to ADAP
ACORDA THERAPEUTICS ORD
NASDAQ Global Select Market
AGIOS PHARMACEUTICALS ORD
NASDAQ Global Select Market
AKERO THERAPEUTICS ORD
NASDAQ Global Select Market
AKOUOS ORD
NASDAQ Global Select Market
ALECTOR ORD
NASDAQ Global Select Market
FAQ
What is the Adaptimmune Therapeutics share price?
As of Today at 19:55 UTC, shares in Adaptimmune Therapeutics are trading at $3.87. This share price information is delayed by 15 minutes.
How has the Adaptimmune Therapeutics share price performed this year?
Shares in Adaptimmune Therapeutics last closed at $3.87 and the price had moved by -56.22% over the past 365 days. In terms of relative price strength the Adaptimmune Therapeutics share price has underperformed the S&P500 Index by -66.79% over the past year.
What are the analyst and broker recommendations for Adaptimmune Therapeutics?
The overall consensus recommendation for Adaptimmune Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Adaptimmune Therapeutics dividend yield?
Adaptimmune Therapeutics does not currently pay a dividend.
Does Adaptimmune Therapeutics pay a dividend?
Adaptimmune Therapeutics does not currently pay a dividend.
When does Adaptimmune Therapeutics next pay dividends?
Adaptimmune Therapeutics does not currently pay a dividend.
How do I buy Adaptimmune Therapeutics shares?
To buy shares in Adaptimmune Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adaptimmune Therapeutics?
As of the previous close price of $3.87, shares in Adaptimmune Therapeutics had a market capitalisation of $601.78m.
Where are Adaptimmune Therapeutics shares listed?
Here are the trading details for Adaptimmune Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ADAP
What kind of share is Adaptimmune Therapeutics?
Based on an overall assessment of its quality, value and momentum Adaptimmune Therapeutics is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adaptimmune Therapeutics share price forecast for 2021?
The analyst consensus target price for shares in Adaptimmune Therapeutics is $61.74. That is 1495.35% above the last closing price of $3.87.
Analysts covering Adaptimmune Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.98 for the next financial year.
What is the trend in the Adaptimmune Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adaptimmune Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -43.41%.
As of the last closing price of $3.87, shares in Adaptimmune Therapeutics were trading -21.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adaptimmune Therapeutics PE Ratio?
We are not able to find PE ratio data for Adaptimmune Therapeutics.
Who are the key directors of Adaptimmune Therapeutics?
Adaptimmune Therapeutics' management team is headed by:
- David Mott - NEC
- Adrian Rawcliffe - CEO
- Gavin Wood -
- William Bertrand -
- Elliot Norry -
- John Lunger -
- Helen Tayton-Martin - OTH
- James Noble - NED
- Lawrence Alleva -
- Ali Behbahani -
- Barbara Duncan -
- John Furey -
- Elliott Sigal -
- Tal Zvi Zaks -
Who are the major shareholders of Adaptimmune Therapeutics?
We do not have data on Adaptimmune Therapeutics' shareholders